Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.
2.

Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.

Syvänne M, Nieminen MS, Frick MH, Kauma H, Majahalme S, Virtanen V, Kesäniemi YA, Pasternack A, Ehnholm C, Taskinen MR.

Circulation. 1998 Nov 10;98(19):1993-9.

4.

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial.

JAMA. 2001 Mar 28;285(12):1585-91.

PMID:
11268266
5.

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.

N Engl J Med. 1999 Aug 5;341(6):410-8.

6.

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.

Post Coronary Artery Bypass Graft Trial Investigators.

N Engl J Med. 1997 Jan 16;336(3):153-62. Erratum in: N Engl J Med 1997 Dec 18;337(25):1859.

7.

The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.

Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, Forrester J, Herd JA, Hoogwerf B, Campeau L, Gobel FL.

Atherosclerosis. 1999 Oct;146(2):369-79.

PMID:
10532693
8.

Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.

Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD Jr, Balagtas CC, Rowan JP, Black DM.

Atherosclerosis. 1996 Nov 15;127(1):113-22.

PMID:
9006811
10.

Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.

Syvänne M, Whittall RA, Turpeinen U, Nieminen MS, Frick MH, Kesäniemi YA, Pasternack A, Humphries SE, Taskinen MR.

Atherosclerosis. 2004 Feb;172(2):267-72.

PMID:
15019536
11.

Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.

Knipscheer HC, Nurmohamed MT, Van den Ende A, Plaat B, Pruijs HJ, Mulder WJ, Kastelein JJ.

J Intern Med. 1994 Oct;236(4):377-84.

PMID:
7931040
12.

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.

Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr.

Ann Intern Med. 2005 Jan 18;142(2):95-104.

PMID:
15657157
14.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

JAMA. 1998 May 27;279(20):1615-22.

PMID:
9613910
15.

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.

Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH.

Circulation. 1992 Jan;85(1):37-45.

PMID:
1728471
16.

Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.

Nyman JA, Martinson MS, Nelson D, Nugent S, Collins D, Wittes J, Fye CL, Wilt TJ, Robins SJ, Bloomfield Rubins H; VA-HIT Study Group.

Arch Intern Med. 2002 Jan 28;162(2):177-82.

PMID:
11802751
17.

Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.

Nikkilä EA, Viikinkoski P, Valle M, Frick MH.

Br Med J (Clin Res Ed). 1984 Jul 28;289(6439):220-3.

18.

Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment.

Karpe F, Taskinen MR, Nieminen MS, Frick MH, Kesäniemi YA, Pasternack A, Hamsten A, Syvänne M.

Atherosclerosis. 2001 Jul;157(1):181-7.

PMID:
11427219
20.

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.

Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.

Metabolism. 2001 Jun;50(6):729-33.

PMID:
11398153

Supplemental Content

Support Center